Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

109.98
-1.2800-1.15%
Post-market: 109.95-0.0300-0.03%19:28 EDT
Volume:8.15M
Turnover:898.78M
Market Cap:136.81B
PE:23.25
High:111.37
Open:110.51
Low:109.48
Close:111.26
Loading ...

BRIEF-Gilead Reports Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study

Reuters
·
21 Apr

Gilead: Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study

THOMSON REUTERS
·
21 Apr

Gilead: Overall Survival (Os), Key Secondary Endpoint, Wasn't Mature at Time of Pfs Primary Analysis

THOMSON REUTERS
·
21 Apr

Gilead: Study Showed Superiority of Trodelvy Plus Keytruda VS Standard of Care (Soc) in 1L Metastatic Triple-Negative Breast Cancer (Mtnbc)

THOMSON REUTERS
·
21 Apr

Gilead: Study Met Main Goal, With Statistically Significant,Clinically Meaningful Improvement in Pfs

THOMSON REUTERS
·
21 Apr

Gilead: Will Continue to Monitor Os Outcomes

THOMSON REUTERS
·
21 Apr

Gilead: Trodelvy Plus Keytruda Shows Early Trend in Improvement for Os VS Soc in Patients With Previously Untreated Pd-L1+ (CPS ≥10) Mtnbc

THOMSON REUTERS
·
21 Apr

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated Pd-L1+ Metastatic Triple-Negative Breast Cancer

THOMSON REUTERS
·
21 Apr

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

Business Wire
·
21 Apr

Gilead Sciences: Strong Financial Outlook and Strategic Positioning Justify Buy Rating

TIPRANKS
·
20 Apr

Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?

Zacks
·
18 Apr

Leerink Partners Adjusts Price Target on Gilead Sciences to $105 From $104, Keeps Outperform Rating

MT Newswires Live
·
17 Apr

Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth

Zacks
·
17 Apr

Nurix Says FDA Clears Oral IRAK4 Degrader Application for Inflammatory Diseases; Shares Up Pre-Bell

MT Newswires Live
·
17 Apr

BRIEF-Nurix Announces FDA Clearance Of Ind Application For Gs-6791/Nx-0479

Reuters
·
17 Apr

Nurix Therapeutics Inc - to Receive $5 Million Milestone Payment From Gilead

THOMSON REUTERS
·
17 Apr

Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know

Zacks
·
17 Apr

Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now?

Insider Monkey
·
16 Apr

Goldman Sachs Adjusts Price Target on Gilead Sciences to $97 From $96, Maintains Neutral Rating

MT Newswires Live
·
15 Apr

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
15 Apr